Nicholas J. Laping

SB-431542 Is a Potent and Specific Inhibitor of Transforming Growth Factor-β Superfamily Type I Activin Receptor-Like Kinase (ALK) Receptors ALK4, ALK5, and ALK7

Gareth J. Inman, Francisco José Nicolás, James F. Callahan et al. · Molecular Pharmacology · 2002 · 1.6K citations

Inhibition of Transforming Growth Factor (TGF)-β1–Induced Extracellular Matrix with a Novel Inhibitor of the TGF-β Type I Receptor Kinase Activity: SB-431542

Nicholas J. Laping, Eugene T. Grygielko, Anil Mathur et al. · Molecular Pharmacology · 2002 · 647 citations

GFAP mRNA increases with age in rat and human brain

Nancy R. Nichols, Jonathan Day, Nicholas J. Laping et al. · Neurobiology of Aging · 1993 · 414 citations

Neurodegenerative Diseases, Alzheimer's Disease, Aging +8

SB-505124 Is a Selective Inhibitor of Transforming Growth Factor-β Type I Receptors ALK4, ALK5, and ALK7

Stacey DaCosta Byfield, Christopher Major, Nicholas J. Laping et al. · Molecular Pharmacology · 2004 · 412 citations

N-((1 S)-1-{[4-((2 S)-2-{[(2,4-Dichlorophenyl)sulfonyl]amino}-3-hydroxypropanoyl)-1-piperazinyl]carbonyl}-3-methylbutyl)-1-benzothiophene-2-carboxamide (GSK1016790A), a Novel and Potent Transient Receptor Potential Vanilloid 4 Channel Agonist Induces Urinary Bladder Contraction and Hyperactivity: Part I

Kevin S. Thorneloe, Anthony C. Sulpizio, Zuojun Lin et al. · Journal of Pharmacology and Experimental Therapeutics · 2008 · 400 citations